#United States #New York #Levi & Korsinsky #Securities Investigation #Myriad Genetics

Myriad Genetics' Recent Performance and Its Consequences

Myriad Genetics (NASDAQ: MYGN) has recently come under significant scrutiny from investors and analysts alike after reporting a disappointing second-quarter revenue for 2026. The company's revenue for this quarter reached approximately $190.7 million, marking an 11% decline compared to the previous year and falling short of Wall Street's consensus expectations, which ranged between $206 million and $208 million. The company has also drastically cut its full-year revenue guidance, now predicting a range of $770 million to $790 million, down from the previous forecast of $860 million to $880 million. This unexpected turn of events has prompted a securities investigation initiated by Levi & Korsinsky, a law firm with a strong track record in securities litigation.

Immediate Impact on Shareholders

As soon as the news of the revenue miss and guidance cut became public, Myriad Genetics saw a sharp drop in its stock prices. For shareholders, this decline represents a significant concern, especially given the implied mismanagement or lack of transparency regarding the company's financial outlook. The law firm Levi & Korsinsky is currently investigating potential violations of securities laws that may have occurred, advising shareholders who have incurred losses to submit their information for potential claims.

The Investigation

The essence of the investigation revolves around whether Myriad Genetics misled investors regarding its financial health and operational performance. Especially telling was the timing of Myriad's guidance reiteration on May 5, 2026, when the company confidently maintained its revenue projections for the year, only to cut those expectations by $90 million within three months. This raises questions about management's communication and transparency with investors.

The Q1 earnings report also lacks clarity, as it indicated trade accounts receivable had risen from $115.3 million at the end of December 2025 to $123.8 million by the end of March 2026—indicating potential collections issues that might have contributed to the unsatisfactory revenue figures.

Management's Rationale

In their explanations, Myriad's management pointed to several factors affecting their revenue. They cited reimbursement pressure, difficult collection processes, reductions in the average revenue per test, and weaker performance in their prenatal testing services. Despite these claims, the abrupt changes in revenue expectations have left many investors feeling blindsided.

Call to Action for Lost Investors

Myriad Genetics shareholders who believe they have suffered financial losses due to these circumstances are encouraged to take immediate steps. Levi & Korsinsky has stated that investors can participate in the investigation whether or not they currently hold the shares, as long as they can provide the necessary documentation that reflects their purchase and sale dates, quantities, and prices. The law firm offers free evaluations for those who wish to understand their eligibility further and explore potential claims against Myriad Genetics.

Conclusion

The financial practices of Myriad Genetics are now under intense scrutiny, and the ongoing investigation by Levi & Korsinsky represents an essential step in holding the company accountable for its actions. The implications for investors are significant, as they may have the opportunity to recover losses stemming from potential securities violations. As the situation develops, it serves as a reminder for shareholders to remain vigilant and informed about their investments and any emerging legal actions that may impact their financial futures.